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Assessment of the Diagnostic Accuracy of Biparametric Magnetic
Resonance Imaging for Prostate Cancer in Biopsy-NaiveMen
The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study
Lars Boesen, MD, PhD; Nis Nørgaard, MD; Vibeke Løgager, MD; Ingegerd Balslev, MD; Rasmus Bisbjerg, MD; Karen-Cecilie Thestrup, MD; Mads D. Winther;
Henrik Jakobsen, MD; Henrik S. Thomsen, DMC
Abstract
IMPORTANCE Multiparametric magnetic resonance imaging (MRI) enhances detection and risk
stratification for significant prostate cancer but is time-consuming (approximately 40minutes) and
expensive. Rapid and simpler (approximately 15-minute) biparametric MRI (bpMRI) using fewer scan
sequences could be implemented as a prostate MRI triage test on a larger scale before performing
biopsies.
OBJECTIVES To assess the diagnostic accuracy and negative predictive value (NPV) of a novel
bpMRI method in biopsy-naive men in detecting and ruling out significant prostate cancer in
confirmatory biopsies.
DESIGN, SETTING, AND PARTICIPANTS A single-institutional, paired, prospective cohort study of
biopsy-naivemenwith clinical suspicion of prostate cancer fromNovember 1, 2015, to June 15, 2017.
INTERVENTIONS All patients underwent bpMRI (T2-weighted and diffusion-weighted imaging)
followed by standard transrectal ultrasound-guided biopsies (all men) and targeted biopsies of men
with suspicious bpMRI findings.
MAINOUTCOMES ANDMEASURES Suspicion grades of bpMRI, biopsy results, and NPV of bpMRI
were evaluated for detection of or ruling out significant prostate cancer (Gleason score4 + 3 or
maximum cancerous core length >50% for Gleason score 3 + 4). We compared the diagnostic
performance of standard biopsies in all men vs standard plus targeted (combined) biopsies
restricted tomenwith suspicious bpMRI findings. The reference standard was combined biopsy
results from all men.
RESULTS A total of 1020menwere enrolled, with a median age of 67 years (interquartile range,
61-71 years) and amedian prostate-specific antigen level of 8.0 ng/mL (interquartile range, 5.7-13.0
ng/mL). Combined biopsies detected any and significant prostate cancer in 655 of 1020men (64%)
and 404 of 1020men (40%), respectively. Restricting combined biopsies to men with suspicious
bpMRI findings meant 305 of 1020men (30%) with low-suspicious bpMRIs could avoid prostate
biopsies (biopsy in 715 menwith suspicious bpMRIs vs all 1020menwho required standard biopsies
[70%]; P < .001). Significant prostate cancer diagnoses were improved by 11% (396 vs 351 men;
P < .001), and insignificant prostate cancer diagnoses were reduced by 40% (173 vs 288men;
P < .001) compared with our current diagnostic standard, standard biopsies alone in all men. The
NPV of bpMRI findings in ruling out significant prostate cancer was 97% (95% CI, 95%-99%).
(continued)
Key Points
Question What are the diagnostic
accuracy and negative predictive value
of novel biparametric magnetic
resonance imaging (MRI) in biopsy-naive
men in detecting and ruling out
significant prostate cancer?
Findings In this cohort study of 1020
menwho underwent both biparametric
targeted and standard transrectal
ultrasound-guided biopsies,
low-suspicion biparametric MRI had a
high negative predictive value (97%) in
ruling out significant prostate cancer on
confirmatory biopsies.
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exclude aggressive disease and avoid
unnecessary biopsies in 30% of men
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cancer, although further studies are
needed to fully explore this new
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE Low-suspicion bpMRI has a high NPV in ruling out significant
prostate cancer in biopsy-naive men. Using a simple and rapid bpMRI method as a triage test seems
to improve risk stratification and may be used to exclude aggressive disease and avoid unnecessary
biopsies with its inherent risks. Future studies are needed to fully explore its role in clinical prostate
cancer management.
JAMA Network Open. 2018;1(2):e180219. doi:10.1001/jamanetworkopen.2018.0219
Introduction
Standard diagnostic transrectal ultrasonography (TRUS)–guided biopsies are offered tomenwith
clinical suspicion of prostate cancer due to elevated prostate-specific antigen (PSA) levels and/or
abnormal digital rectal examination results. However, men without prostate cancer undergo
unnecessary biopsies because elevated PSA is not cancer specific. Given the high false-positive rate
of PSA, its use for screening purposes is controversial and an area of continuous debate within the
medical and urological communities.1 As standard biopsies are prone to sampling errors because of
difficulties in prostate cancer target identification on TRUS, clinically significant prostate cancer may
bemissed and insignificant prostate cancer detected by the random untargeted sampling,
potentially leading to overdetection and overtreatment.2 In addition, biopsies are invasive andmay
lead to patient anxiety and morbidity.3 These limitations have highlighted the need for better
diagnostic tools, such as risk calculators, biomarkers, or imaging techniques,4 to improve selection of
men with increased risk of significant prostate cancer who require diagnostic biopsies and
subsequent treatment from the proportion of men with either a benign condition or an insignificant
prostate cancer that can be managed with expectancy. However, risk calculators are highly
influenced by the population studied and newer biomarkers can be costly, may be limited by
availability, and have not yet been proven to have the desired level of accuracy in biopsy-naive men
with prostate cancer.5,6 Accurate methods that improve detection of significant prostate cancer
while minimizing overdetection and unnecessary biopsies by reducing the number of false-positive
results are highly warranted. Growing evidence supports the use of multiparametric magnetic
resonance imaging (mpMRI) to solve this problem.7,8 Magnetic resonance imaging–guided biopsies
(targeted biopsies) can be targeted toward the most aggressive part of suspicious lesions detected
by mpMRI, improving the detection of significant prostate cancer compared with standard biopsies
alone.9-12 Conversely, low-suspicion mpMRI may noninvasively exclude the presence of aggressive
disease.13 Accordingly, mpMRI could potentially be used as a triage test to identify biopsy-naive men
with clinical suspicion of prostate cancer whomight safely avoid unnecessary biopsies.
However, guidelines on prostate MRI14-16 recommend a full mpMRI prostate examination that
includes several anatomical and functional scan sequences as well as intravenous contrast media.
This is time-consuming (approximately 40minutes), expensive, andmight be difficult to implement
on a large scale. Over time it has become evident that contrast-enhanced imaging andmultiple
imaging planes often do little to improve the overall clinical picture, especially in the detection and
localization of significant prostate cancer. In contrast, a rapid and simple biparametric MRI (bpMRI)
method that uses fewer scan sequences and no intravenous contrast media might decrease image
acquisition time (approximately 15 minutes) and costs, while retaining sufficient diagnostic accuracy
to detect and rule out significant prostate cancer in biopsy-naivemen. Such a bpMRI protocol could
provide a basis for a prostate MRI triage test prior to biopsy. Consequently, this prospective study
assesses the diagnostic accuracy of bpMRI in detecting and ruling out significant prostate cancer in
biopsy-naive men with clinical suspicion of prostate cancer. We evaluated the clinical significance of
detected cancers and assessed whether bpMRI could be used as a triage test to improve the
diagnosis of significant prostate cancer and identify patients who could safely avoid unnecessary
biopsies.
JAMANetworkOpen | Urology Diagnostic Accuracy of Biparametric MRI for Detecting Prostate Cancer in Biopsy-Naive Men
JAMA Network Open. 2018;1(2):e180219. doi:10.1001/jamanetworkopen.2018.0219 June 8, 2018 2/12
Downloaded From: https://jamanetwork.com/ by a Copenhagen University Library User  on 03/29/2019
Methods
This Biparametric MRI for Detection of Prostate Cancer (BIDOC) study is a prospective, single-
institution, paired-cohort study. It was approved by the Local Committee for Health Research Ethics
and the Danish Data Protection Agency. Participants provided written informed consent and were
enrolled from November 1, 2015, to June 15, 2017. This study conformed to the Standards of
Reporting for MRI-Targeted Biopsy Studies consortium criteria for MRI biopsy studies17 and adhered
to the Standards for Reporting of Diagnostic Accuracy (STARD) reporting guideline criteria.18 The study
inclusion criteria required all men to have clinical suspicion of prostate cancer (PSA4 ng/mL [to
convert to micrograms per liter, multiply by 1.0] and/or abnormal digital rectal examination results)
thatwarranted a diagnostic prostate biopsy. The exclusion criteriawere prior prostate biopsies, evidence
of acute urinary tract infections, acute prostatitis, general contraindications forMRI (eg, claustrophobia,
a pacemaker, metal implants), and prior hip replacement surgery or other metallic implants in the
pelvic area.
OutcomeMeasures
The primary end points were the diagnostic accuracy and negative predictive value (NPV) of
low-suspicion bpMRI findings in ruling out significant prostate cancer in confirmatory biopsies from
biopsy-naive men. Secondary end points included the overall prostate cancer detection rate and
detection rates of significant prostate cancer and insignificant prostate cancer stratified by biopsy
technique. We also evaluated the clinical value of using bpMRI as a triage test prior to biopsies and
estimated the proportion of men who could safely avoid unnecessary biopsies based on
low-suspicion bpMRI findings.
bpMRI (Index Test) and ImageAnalysis
Prior to biopsies, bpMRI was performed using a 3-T MRI magnet (Philips Healthcare) with a pelvic-
phased-array coil (Philips Healthcare) positioned over the pelvis. The bpMRI protocol included axial
T2-weighted and diffusion-weighted images (b values: 0, 100, 800, and 2000) with reconstructions
of the corresponding apparent diffusion coefficient map, because these 2 parameters are the
dominant sequences for prostate cancer lesion detection onmpMRI.15 A sagittal T2-weighted luxury
scout image supported the axial sequences for MRI/TRUS image fusion. The overall bpMRI image
acquisition time was approximately 15 minutes. Imaging parameters are listed in eTable 1 in the
Supplement.
All bpMRI images were reviewed by the same prostate MRI physician (>5 years of experience)
blinded to clinical findings. Suspicious lesions were scored on a 5-point scale according the Prostate
Imaging Reporting andData System version 2 (PI-RADSv2) criteria.15 However, as the bpMRI protocol
does not include dynamic contrast-enhanced imaging, scoring of lesions in the peripheral zone relied
solely on diffusion-weighted image findings (dominant sequence), and an equivocal score of 3 was
not potentially upgraded to a score of 4 due to lack of positive dynamic contrast-enhanced findings.
All patients were graded overall using this modified PI-RADS score according to their likelihood of
having significant prostate cancer (1, highly unlikely; 2, unlikely; 3, equivocal; 4, likely; and 5, highly
likely). Amodified PI-RADS suspicion score of 2 or lower was perceived as a low-suspicion or negative
bpMRI scan result. Patients with no suspicious lesions were assigned an overall modified PI-RADS
score of 1.
Standard and Targeted Biopsies
Initially, all patients underwent systematic standard biopsies (10-core extended sextant biopsy
scheme) according to guidelines.19 Any suspicious lesion detected by TRUSwas sampled as part of
the standard biopsy scheme. Standard biopsies were immediately followed by additional targeted
biopsies of any bpMRI suspicious lesions (modified PI-RADS3; 1-2 cores/lesion) using 1 of 2 rigid
MRI/TRUS image-fusion systems: HI-RVS system (Hitachi; n = 877) and Uro-Nav system (Invivo;
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n = 143) for men biopsied. All prostate biopsies were potted separately and obtained using an
end-fire biopsy technique by 1 of 2 operators with extensive experience in performing standard
biopsies and reasonable experience in software-based image fusion for targeted biopsies (4 years
and 1 year). Performance and analysis of standard biopsies and bpMRI were blinded with respect to
each other.
Histopathological Evaluation and Cancer Significance
All biopsy samples were reviewed by the same genitourinary pathologist (>15 years of experience).
For each prostate cancer-positive biopsy core, the location, Gleason score (GS) based on the
International Society of Urological Pathology 2005 consensus,20 and percentage of cancerous tissue
per core were determined. In addition, patients were allocated using the International Society of
Urological Pathology 2014 consensus Gleason-grade groups21 based on the GS scoring criteria.20 The
primary definition of significant prostate cancer included both cancer GS grade and volume, and
significant prostate cancer was defined as any core with high-grade prostate cancer (GS7 [4 + 3])
or maximum cancerous core length greater than 50% of GS 7 (3 + 4) prostate cancer. Other
definitions of significant prostate cancer were additionally assessed.
Statistical Analysis
Patient characteristics were stratified by biopsy results and reported using descriptive statistics.
Continuous variables (eg, age, PSA level, PSA density, and prostate volume) were compared using
theWilcoxon rank sum test. Fisher exact test was used to compare the clinical tumor stage
determined by digital rectal examination pooled in nonpalpable and palpable tumor groups.
Prebiopsy bpMRI suspicion (modified PI-RADS) scores were compared with biopsy results using a χ2
analysis to determine the association between bpMRI suspicion and positive biopsy findings. We
compared the diagnostic performances of the following clinical strategies: (1) standard biopsies in all
men, (2) standard plus targeted (combined) biopsies restricted tomenwith suspicious bpMRIs, and
(3) combined biopsies in all men, which served as reference standard. Any patient with significant
prostate cancer in either standard or targeted biopsies was classified as having significant prostate
cancer on combined biopsies. A McNemar test was used to compare prostate cancer detection rates
between biopsy strategies in 2 × 2 contingency tables. The sensitivity and NPV for detecting and
ruling out any prostate cancer and significant prostate cancer comparing standard biopsies in all men
vs combined biopsies restricted tomenwith suspicious bpMRIs were calculated to assess our
primary outcomemeasures. Furthermore, the clinical value of the biopsy strategies comparing
benefits (significant prostate cancer detection) and harms (unnecessary biopsies) were evaluated
using net benefit and decision curve analyses. All anayses were 2-tailed and a P value of less than .05
was considered significant. Statistical analyses were performed using SPSS statistical software
version 22.0 (SPSS Inc).
Results
A total of 1063menwere prospectively enrolled and 43were excluded for various reasons (Figure 1).
The final study population consisted of 1020menwith amedian age of 67 years (interquartile range,
61-71 years) and amedian PSA level of 8.0 ng/mL (interquartile range, 5.7-13.0 ng/mL). The patients’
demographic data and baseline characteristics are listed in Table 1. Overall, prostate cancer was
detected in 655 of 1020 men (64%), and 404 of 1020 men (40%) had significant prostate cancer
according to the primary definition. Standard biopsies detected prostate cancer and significant
prostate cancer in 639 of 1020men (63%) and 351 of 1020men (34%), respectively, with 402 of 639
men (63%) having lower-grade prostate cancer (Gleason-grade group 1 or 2). We found a lower NPV
for any prostate cancer (72%) for a modified PI-RADS score of 3 or higher, but a higher NPV for
significant prostate cancer (97%). Targeted biopsies were performed for 715 of 1020men (70%)
with suspicious bpMRIs (modified PI-RADS3) and detected prostate cancer and significant
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prostate cancer in 478 of 715 men (67%) and 338 of 715 men (47%), respectively. Patients with
low-suspicion bpMRIs (305men [30%]) did not have targeted biopsies. Of these, standard biopsies
detected prostate cancer in 86 of 305men (28% [8%of the entire cohort]) stratified into 78 of 305
men (26% [8% of the entire cohort]) with insignificant prostate cancer and 8 of 305men (3% [0.8%
of the entire cohort]) with significant prostate cancer (Table 2).
The bpMRI modified PI-RADS suspicion scores were associated with the biopsy results
(P < .001) (eFigure 1 in the Supplement). The diagnostic yield of significant prostate cancer increased
at higher modified PI-RADS scores, and there was a significantly lower significant prostate cancer
detection rate in menwith low-suspicion bpMRI findings compared with menwho had highly
Figure 1. Flowchart of the Study Population
1063 Included patients with clinical
suspicion of prostate cancer
(elevated prostate-specific
antigen and/or abnormal
digital rectal examination
findings)
1027 Completed bpMRI
1023 Completed bpMRI and biopsies
1020 Final study population
bpMRI (index test)
36 Patients withdrew before or
during MRI
3 Claustrophobia
8 Incomplete MRI data
5 Diffusion artefact
3 Failed MRI appointment
24 Did not wish to participate
after enrollment
1 Clinical reason
(acute hepatitis)
Combined biopsy (standard biopsies
[test 2] followed by bpMRI targeted
biopsies [test 3])
4 Patients withdrew before or
during biopsy
2 Incomplete ultrasonographic
or biopsy data
2 Did not wish to participate
after bpMRI
3 Patients withdrew after
examinations
2 Clinical reasons
1 Neuroendocrine tumor,
no Gleason score
1 Biopsies showed B-cell
lymphoma
1 Did not wish to participate
after bpMRI
A total of 1063menwere included. However, 43 were
excluded for various reasons. The final study
population consisted of 1020menwho completed all
examinations. MRI indicates magnetic resonance
imaging; bpMRI, biparametric MRI.
Table 1. Patient Characteristics
Clinical Characteristic
Prostate Cancer
Negative (n = 365)
Prostate Cancer
Positive (n = 655)a P Value Total (N = 1020)
Age, median (IQR), y 64 (59-69) 68 (62-72) <.001 67 (61-71)
PSA, median (IQR), ng/mL 6.4 (5.2-8.9) 9.2 (6.1-19.9) .03 8.0 (5.7-13.0)
Prostate volume, median (IQR), cm3 65 (49-88) 47 (36-61) <.001 53 (40-72)
PSA density, median (IQR), ng/mL/cm3 0.10 (0.07-0.14) 0.20 (0.12-0.43) <.001 0.15 (0.10-0.27)
Time from bpMRI to biopsy,
median (IQR), d
7 (4-11) 7 (5-9) .44 7 (7-9)
cTDRE stage, No. (%)
Nonpalpable tumor
<.001b
Tx 106 (29) 69 (11) 175 (17)
T1c 208 (57) 260 (40) 468 (46)
Palpable tumor
T2 46 (13) 199 (30) 245 (24)
T3 5 (1) 120 (18) 125 (12)
T4 0 7 (1) 7 (1)
Abbreviations: bpMRI, biparametric magnetic
resonance imaging; cTDRE, tumor stage determined by
digital rectal examination; IQR, interquartile range;
PSA, prostate-specific antigen.
SI conversion factor: To convert PSA tomicrograms per
liter, multiply by 1.0.
a Based on biopsy results of combined biopsies in
all men.
b A Fisher exact test was used to compare the cTDRE
stage pooled in nonpalpable and palpable
tumor groups.
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suspicious (modified PI-RADS 4-5) bpMRI findings (8 of 305 [3%, or 0.8% of the entire cohort] vs
379 of 585 [65%, or 57% of the entire cohort]; P < .001). The diagnostic performances of standard
and combined biopsies are shown in Figure 2. The value of using bpMRI as a diagnostic triage test to
identify menmost suitable for prostate biopsies—to identify significant prostate cancers and avoid
unnecessary biopsies—was assessed by comparing standard biopsies in all men vs combined biopsies
restricted tomenwith suspicious bpMRIs (Table 3). Restricting combined biopsies to menwith
suspicious bpMRI findings meant 305 of 1020men (30%) with low-suspicious bpMRIs could avoid
primary prostate biopsies (biopsy 715 men with suspicious bpMRIs vs all 1020 men who required
standard biopsies [70%]; P < .001). Significant prostate cancer diagnoses were improved by 11% (4%
absolute improvement; 396 vs 351 men; P < .001), and insignificant prostate cancer diagnoses were
reduced by 40% (11% absolute reduction; 173 vs 288men; P < .001) using fewer biopsy cores
compared with standard biopsies alone. The NPV of bpMRI findings in ruling out significant cancer
was 97% (95% CI, 95%-99%). Standard biopsies detected significant prostate cancer in 8menwith
modified PI-RADS scores of 2 or lower (eTable 2 in the Supplement). Other definitions of significant
prostate cancer were also used to evaluate the 2 biopsy strategies (Table 3). Although the prevalence
of significant prostate cancers changedwhen other definitionswere used, the reduction in diagnoses
Table 2. Comparison of bpMRI Suspicion ScoresWith Biopsy Gleason Scores and Grade Groupsa
bpMRI Modified
PI-RADSb
Combined Biopsies, No.c
No Prostate Cancer
Insignificant Prostate Cancer Significant Prostate Cancer
TotalGS 6, GGG 1
GS 3 + 4, GGG 2,
MCCL ≤50%
GS 3 + 4, GGG 2,
MCCL >50%
GS 4 + 3,
GGG 3 GS 8, GGG 4
GS 9 to 10,
GGG 5
1 123 44 8 1 2 2 1 181
2 97 20 5 0 2 0 0 124
3 64 38 11 7 6 2 2 130
4 47 38 29 29 22 15 7 187
5 35 39 18 74 76 64 92 398
Total 366 179 71 111 108 83 102 1020
Abbreviations: bpMRI, biparametric magnetic resonance imaging; GGG, Gleason-grade
group; GS, Gleason score; MCCL, maximum cancer-core length; PI-RADS, Prostate
Imaging Reporting and Data System.
a Biopsy results of all patients were stratified by GS/GGG and bpMRI modified PI-RADS.
Gleason-grade group 2 (GS 3 + 4) was subdivided into 2 groups (MCCL50% and
MCCL >50%).
b A bpMRI modified PI-RADS score of 1 or 2 indicates low-suspicion or negative bpMRI
findings; a bpMRImodified PI-RADS score of 3 or 5 indicates suspicious bpMRI findings.
c Patients with a modified PI-RADS score of 1 or 2 only underwent standard transrectal
ultrasound-guided biopsies. Combined biopsies are standard plus targeted.
Figure 2. Comparison of the Diagnostic Performances of Biopsy Strategies
0
Combined Biopsies
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in All Men
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The diagnostic performance consisted of standard
biopsies in all men (N = 1020), combined (standard
plus targeted) biopsies restricted tomenwith
suspicious biparametric magnetic resonance imaging
(bpMRI) findings (n = 715), and combined biopsies in
all men (reference standard) (N = 1020). Biopsy results
were stratified by cancer significance (primary
definition). insPCa indicates insignificant prostate
cancer; PCa, prostate cancer; PImod, modified Prostate
Imaging Reporting and Data System score;
and sPCa, significant PCa.
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in men with insignificant prostate cancer when bpMRI was used as a triage test did not change
markedly. However, for the tertiary definition of significant prostate cancer (GS3 + 4), the
detection rate for the comparison between standard and combined biopsies did not reach the level
of statistical significance (McNemar test, P = .11). Sensitivities, NPVs, and net benefit with decision
curve analyses are compared in Table 4 and eFigure 2 in the Supplement. Furthermore, restricting
combined biopsies to menwith suspicious bpMRIs compared with performing combined biopsies in
all men reduced overdiagnosis of insignificant prostate cancer by 31% (n = 77; 173 vs 250men).
Discussion
This study showed that a low-suspicion bpMRI had a high NPV in ruling out significant prostate
cancer in confirmatory biopsies. The results suggest that bpMRI may be used as a triage test to
exclude the presence of aggressive disease and avoid unnecessary biopsies with its inherent
complications (severe infection, rectal bleeding, etc).3,22 Biparametric MRI suspicion scores were
associated with prostate cancer detection rates, and performing combined biopsies (standard and
targeted) in all men significantly enhanced the detection of significant prostate cancer compared
with standard biopsies alone, which is the recommended diagnostic standard approach in biopsy-
naive men. If combined biopsies were restricted solely to patients with suspicious bpMRIs, only 8
menwith significant prostate cancer would have beenmissed and significantly fewer men (n = 77)
with insignificant prostate cancer would have been diagnosed. Therefore, 305 of 1020 men (30%)
could have safely avoided biopsies because most of these men had low-risk disease qualifying for
surveillance. Reducing overdiagnoses of insignificant prostate cancer compared with standard
biopsies (−40%) or combined biopsies in all men (−31%)might also reduce overtreatment.2
Our findings are consistent with those of the PROMIS study by Ahmed et al7 that provided level
1b evidence for the diagnostic accuracy ofMRI in detecting prostate cancer. Those findings suggested
that if mpMRI were used as a triage test, 1 in 4menmight safely avoid prostate biopsies and the
diagnostic ratio of significant prostate cancer vs insignificant prostate cancer would be improved. In
Table 3. Comparison of Biopsy Strategya
Significant Prostate Cancer
Definition
Biopsies, No. (% [95% CI])b Difference, % (95% CI)
P Value,
McNemar TestStandard (All Men)
Combined
(modified PI-RADS 3-5) Absolute Relative
Men with biopsy performed 1020 (100 [99 to 100]) 715 (70 [67 to 73]) –30 (–33 to –27) –30 (–33 to –27) <.001
Biopsy cores, No. 9268 7339c –21 (–22 to –20) –21 (–22 to –20) <.001
No prostate cancer on biopsy 381 (37 [34 to 40]) 146 (14 [12 to 17]) –23 (–27 to –19) –62 (–68 to –55) <.001
Primary definition of significant
prostate cancerd
Insignificant prostate cancer 288 (28 [26 to 31]) 173 (17 [15 to 19]) –11 (–15 to –8) –40 (–49 to –29) <.001
Significant prostate cancer 351 (34 [32 to 37]) 396 (39 [36 to 42]) 4 (0.2 to 9) 11 (0.6 to 21) <.001
Secondary definition of significant
prostate cancere
Insignificant prostate cancer 262 (25 [23 to 29]) 145 (14 [12 to 17]) –11 (–15 to –8) –45 (–54 to –34) <.001
Significant prostate cancer 377 (37 [34 to 40]) 424 (42 [39 to 45]) 5 (0.4 to 9) 11 (0.9 to 21) <.001
Tertiary definition of significant
prostate cancerf
Insignificant prostate cancer 198 (19 [17 to 22]) 115 (11 [9 to 13]) –8 (–11 to –5) –42 (–53 to –28) <.001
Significant prostate cancer 441 (43 [40 to 46]) 454 (45 [41 to 48]) 1 ( to 3 to 6) 3 (−7 to 12) .11
Abbreviation: PI-RADS, Prostate Imaging Reporting and Data System.
a Comparison of the diagnostic strategies of standard biopsies in all men vs combined
(standard plus targeted) biopsies restricted to men with suspicious biparametric
magnetic resonance imaging findings (modified PI-RADS score 3-5) using different
definitions of significant prostate cancer.
b The total number of patients (N = 1020) was used as the denominator for calculating
all percentages.
c Includes 6231 standard biopsies and 1108 targeted biopsies.
d Gleason score of 4 + 3 or greater or maximum cancer-core length greater than 50%
with a Gleason score of 3 + 4. The prevalence was 404men (40% [95% CI,
37%-43%]).
e Gleason score of 4 + 3 or greater or maximum cancer-core length greater than 50%
with any PCa. The prevalence was 436men (43% [95% CI, 40%-46%]).
f Gleason score of 3 + 4 or greater. The prevalence was 475men (47% [95% CI,
44%-50%]).
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addition, the results from the PROTECT study by Hamdy et al23 were a critical landmark in showing
that overdiagnosis and overtreatment of low-risk disease, resulting from the standard biopsy
approach, showedminimal patient survival benefits, although it did decrease metastasis rates. The
fact that more than three-fourths of the included patients had low-risk disease (the rest mostly
intermediate risk) emphasizes the need to avoid biopsies and overtreatment of men.
Prior studies evaluated the diagnostic accuracy of bpMRI alone,24 combined with PSA levels,25
or compared with mpMRI.26 In a recent study of 161 biopsy-naive men who underwent bpMRI
followed by targeted and standard biopsies, Jambor et al24 found that restricting biopsies to men
with equivocal to highly suspicious bpMRI findings reduced the number of men undergoing biopsies
by 24%, while failing to detect only 2%with significant prostate cancer. Although their results are
similar to ours, Jambor and colleagues used a different bpMRI scoring system, they relied on
cognitive targeted biopsies, and their biopsy operator was not blinded to the bpMRI findings before
performing standard biopsies.
At present, the US Preventive Services Task Force recommends that PSA screening should be
based on shared decision making and patient preferences for men aged 55 to 69 years. However,
opponents of screening argue that the test has no net benefit and the harms (eg, high false-positive
rate, overdetection of insignificant prostate cancer, and biopsy complications) outweigh the benefits
demonstrated in randomized clinical trials.27-29 However, usingMRI as a secondary triage test inmen
with elevated PSA levels could potentiallyminimize uncertainties and improve the balance between
benefits and harms by reducing the number of false-positive PSA results that would otherwise lead
Table 4. Comparison of Sensitivities and NPVs
Prostate Cancer Definitiona
% (95% CI)
bpMRI Modified PI-RADS
3-5 (n = 715)b
Standard Biopsies, All Men
(N = 1020)
Combined Biopsies, Modified
PI-RADS 3-5 (n = 715)
Any prostate cancerc
Sensitivity 86 (84-89) 98 (96-99) 86 (84-89)
NPV 72 (67-76) 96 (93-97) 81 (78-84)
Significant prostate cancer,
primary definitiond
Sensitivity 98 (96-99) 87 (83-90) 98 (96-99)
NPV 97 (95-99) 92 (90-94) 99 (97-99)
Significant prostate cancer,
secondary definitione
Sensitivity 97 (95-99) 86 (83-90) 97 (95-99)
NPV 96 (93-98) 91 (89-93) 98 (97-99)
Significant prostate cancer,
tertiary definitionf
Sensitivity 96 (93-97) 93 (90-95) 96 (93-97)
NPV 93 (90-95) 94 (92-96) 96 (94-98)
Abbreviations: bpMRI, biparametric magnetic resonance imaging; NPV, negative predictive value; PI-RADS, Prostate
Imaging Reporting and Data System.
a The sensitivities and NPVs for detecting and ruling out any PCa and sPCa are shown for bpMRI alone and for the 2
diagnostic strategies (1) standard biopsies in all men and (2) combined biopsies (standard plus targeted) restricted to
menwith suspicious bpMRIs (modified PI-RADS 3-5) using various definitions of significant PCa. Overall detection rates
of PCa and sPCa in combined standard transrectal ultrasonography-guided biopsies and bpMRI targeted biopsies of all
patients was used as the reference standard.
b The bpMRI score was dichotomized by low-suspicion or negative bpMRI findings (modified PI-RADS 1-2) and suspicious
bpMRI findings (modified PI-RADS 3-5).
c Prevalence was 655men (64% [95% CI, 61%-67%]).
d Gleason score of 4 + 3 or greater or maximum cancer-core length greater than 50%with a Gleason score of 3 + 4. The
prevalence was 404men (40% [95% CI, 37%-43%]).
e Gleason score of 4 + 3 or greater or maximum cancer-core length greater than 50%with any PCa. The prevalence was
436men (43% [95% CI, 40%-46%]).
f Gleason score of 3 + 4 or greater. The prevalence was 475men (47% [95% CI, 44%-50%]).
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to unnecessary invasive biopsies. The net benefit and decision curve analyses in our study showed
that restricting biopsies to men with suspicious (modified PI-RADS 3-5) bpMRI lesions achieved the
highest clinical value for all threshold probabilities compared with our current practice—standard
biopsies in all men. However, at very low biopsy threshold probabilities, the preferable approach is to
perform combined biopsies in all men. Assuming that no urologist would routinely carry out a biopsy
in amanwith less than a 5% risk of significant prostate cancer (equivalent to performing biopsies in
20 men to find 1 additional significant prostate cancer), using bpMRI to determine whether to
perform a biopsy achieved the best clinical outcome balancing benefits and harms.
In general, we should cautiously consider using bpMRI or mpMRI as a triage test to identify
individuals who can avoid prostate biopsies. Numerous factors, including image quality,
interpretation, and definition of significant prostate cancer including disease prevalence, can affect
the performance of targeted biopsies and the NPV of an MRI. A recent meta-analysis found that the
medianmpMRI NPVs (suspicion score3) for ruling out any prostate cancer and significant prostate
cancer were 82%and 88%, respectively. However, these valueswere strongly influenced by disease
prevalence in the populations studied.13 We found a lower NPV for any prostate cancer (72%) for a
modified PI-RADS score of 3 or higher, but a higher NPV for significant prostate cancer (97%),
although the definitions of significant prostate cancer differed. PerformingMRI can be expensive and
time-consuming, and it would be amajor challenge for any health care system to systematically use
mpMRIs to diagnose prostate cancer before all biopsies. However, our results confirm that a more
rapid and simple bpMRI approach is feasible, is sufficient for MRI/TRUS image fusion, and provides an
accurate sectormap of the prostate for targeted biopsies. It improves prostate cancer detection and
risk stratification in biopsy-naive men andmaintains the high diagnostic accuracy of mpMRI.30,31 Kuhl
et al26 found no significant differences in the diagnostic accuracy of bpMRI andmpMRI in 542men
with elevated PSA who underwent repeated biopsies. However, it is important to note that a
low-suspicion bpMRI did not unequivocally rule out any prostate cancer. Nevertheless, the key
concern in clinical practice is to detect and rule out significant disease while avoiding unnecessary
biopsies.
Limitations
Our study had limitations. It was performed at a single center with 1 dedicatedMRI physician reading
the bpMRIs and 2 highly experienced TRUS operators performing biopsies. As a result, no interreader
variability analyses were done. Less experienced readers and operators might not achieve the same
diagnostic yield. Further work would be necessary to evaluate variability between experts and
nonexperts. Second, all the patients in our study were from a non-PSA-screened population in whom
benign reasons for elevated PSA levels (eg, urinary retention, urinary tract infections) had been ruled
out before inclusion. This might explain both the rather high prostate cancer detection rate using
standard biopsies and the higher median PSA level (8.0 ng/mL) compared with other studies.7,11,12,24
The diagnostic accuracy and NPVs of bpMRIsmight be different in other patient populations. Third,
we used biopsy results comparatively in this study, and the combined biopsy results from all patients
were used as the reference standard. There may have been undetected prostate cancer lesions in
both standard and targeted biopsy procedures, and the true rate of false-negative readings cannot
be assessed. Nevertheless, we performed standard biopsies on all study participants, including those
with low-suspicion bpMRI findings. This enabled us to compare outcomes among the different
biopsy techniques andmake comparisons that reflect clinical practice. Finally, the criteria for
significant prostate cancer diagnoses depended on the histopathological assessment of biopsies.
Although our definition is similar to that used in the PROMIS study by Ahmed et al,7 other
investigators have used and suggested different definitions that might change the overall diagnostic
accuracy of bpMRIs. A clear consensus for defining significant prostate cancer inMRI biopsy studies
will be required to allow interstudy comparisons and to develop redefined risk calculators that
include biopsy results from additional MRI targeted biopsies, as most of the currently available
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predictive nomograms and risk calculators are based on standard biopsy results with the inherent
limitations of standard biopsy.
Despite these limitations, our data provide evidence for the reliability of using low-suspicion
bpMRI findings as a noninvasive diagnostic tool to rule out more aggressive prostate cancer and
avoid unnecessary biopsies. Although the use of prebiopsy bpMRI and targeted biopsies significantly
improve risk stratification and could benefit clinical practice, the cost-effectiveness and long-term
health outcomes using MRI have not been fully explored. Follow-up data and the long-term
outcomes of these study patients will be assessed in the future. Furthermore, because bpMRI is a
new diagnostic imaging approach, further studies are needed to validate our findings and fully
explore the role of bpMRI in prostate cancer management before more widespread implementation
into clinical practice.
Conclusions
Low-suspicion bpMRI has a high NPV in ruling out significant disease in biopsy-naivemenwith clinical
suspicion of prostate cancer. Furthermore, bpMRI suspicion scores are strongly associated with
prostate cancer detection rates and performing biopsies (standard plus targeted) only in men with
suspicious bpMRI findings is the preferred approach for improving the diagnostic ratio of significant
prostate cancer to insignificant prostate cancer compared with our current diagnostic standard—
standard biopsies in all men. Therefore, bpMRI used as a triage test improves risk stratification and
allows for 30% of menwith clinical suspicion of prostate cancer to safely avoid unnecessary prostate
biopsies with their inherent risks. Further studies are needed to fully explore its future role in clinical
prostate cancer management.
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